Littleton, CO (PRWEB) February 18, 2016
CereScan was recently awarded a $250,000 grant from the State of Colorado, which will be used to further develop the capabilities of its patented CereMetrix™ Brain Diagnostic System. The grant will allow the company to commercialize CereMetrix™ for use by hospitals, clinics, physicians, and other healthcare practitioners as an advanced utility for diagnosis, treatment and research into most neurological disorders.
CereMetrix is a unique brain diagnostic system and ever-expanding data warehouse that today includes 6,600 scan encounters including patients’ medical histories, family histories, symptoms, prior treatments, incoming diagnoses, outgoing diagnoses, and brain scans. Each scan is composed of over 262,000 data points that measure perfusion levels in up to 160 brain regions derived from comparisons to normative data.
The commercialization of CereMetrix™ is expected to create high-paying, professional job opportunities in the state and long-term economic gains as the system progresses through its development and eventual licensure to domestic and international users. CereMetrix™ will become a software-as-a-service system that will assist healthcare practitioners in the diagnosis of complex brain disorders.
“We are excited to receive such a strong endorsement from the state of Colorado for the work we are doing and the vision we are pursuing,” said Dr. Rick Fort, Chief Science Officer at CereScan. “CereMetrix™ will become a clinical decision support system that doctors will be able to use in the diagnosis of their patients’ brain dysfunctions anytime, anywhere.”
The vision of CereMetrix™ is a machine learning ecosystem that provides doctors with the most likely diagnoses and treatment regimens for their patient’s brain health. Each new patient’s data will be compared to a library of patients with similar brain patterns, medical histories, and clinical symptoms.
CereScan, is the nation’s leader in providing statistically measured brain diagnostics based on a new generation of imaging software, PET/CT (Positron Emission Tomography/Computed Tomography) and qSPECT (quantitative Single Photon Emission Computed Tomography) neuroimaging technologies. Referring and treating medical experts can rely on CereScan to offer differentiated diagnoses on a wide array of brain-based disorders including:
- Traumatic Brain Injury
- Toxic Brain Injury
- Alzheimer’s Disease
- Mild Cognitive Impairment
- Other Dementias
- Parkinson’s Disease
- Obsessive Compulsive Disorder
- Bipolar Disorder
- Anxiety Disorder
CereScan combines state-of-the-art qSPECT and PET/CT brain imaging technologies with a patient centered model of care to provide the highest level of neurodiagnostics anywhere. Using quantitative functional brain imaging, advanced imaging software, and an extensive library of clinical data, the CereScan medical team provides physicians with unmatched objective diagnostic information. CereScan helps patients and their physicians better understand the neurological basis of their conditions. In a variety of legal settings, CereScan provides objective evidence to attorneys and their clients regarding traumatic and toxic brain injuries. For researchers, CereScan provides independent pre- and post-treatment measures of organic changes in the brain along with measures of symptoms related to the brain disorder of interest. For more information, please call (866) 722-4806 or visit http://www.CereScan.com. Connect with CereScan on Twitter @CereScan and on Facebook at Facebook.com/CereScan.